BioCentury
ARTICLE | Clinical News

NuCana gains on first-line biliary cancer readout

January 19, 2018 9:51 PM UTC

NuCana plc (NASDAQ:NCNA) jumped $6.02 (42%) to $20.51 on Friday after reporting interim data from the Phase Ib ABC-08 trial showing that Acelarin (NUC-1031) plus cisplatin as first-line treatment led to an objective response rate (ORR) of 50% in eight evaluable patients with advanced biliary tract cancer. Data were presented at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium in San Francisco.

This year, NuCana plans to start a Phase III trial of Acelarin in the first-line biliary tract cancer indication. The product is a modified version of gemcitabine that uses ProTide technology from Morvus Technology Ltd. (Llanvetherine, U.K.)...